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Pneumococcal colonization is rarely studied in adults, except as 
part of family surveys. We report the outcomes of colonization 
screening in healthy adults (all were nonsmokers without major 
comorbidities or contact with children aged <5 years) who had 
volunteered to take part in clinical research. Using nasal wash 
culture, we detected colonization in 6.5% of volunteers (52 of 
795). Serotype 3 was the commonest serotype (10 of 52 isolates). 
The majority of the remaining serotypes (35 of 52 isolates) were 
nonvaccine serotypes, but we also identified persistent circu-
lation of serotypes 19A and 19F. Resistance to at least 1 of 6 
antibiotics tested was found in 8 of 52 isolates.
Keywords. Drug resistance; microbial; herd immunity; 
nasal washing; Streptococcus pneumoniae.
Colonization with Streptococcus pneumoniae is a key precursor 
to invasive pneumococcal disease (IPD). Colonization is more 
common in children than in adults, and contact with children 
aged <5 years is the main risk factor for adult colonization [1]. 
Pneumococcal conjugate vaccines (PCVs) prevent pediatric 
pneumococcal disease and induce herd protection against vac-
cine serotypes through reductions in colonization in vaccinated 
children and, indirectly, unvaccinated adults [2].
In the United Kingdom, PCV13 (covering serotypes 1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F) was introduced 
to the national immunization program in April 2010, replacing 
PCV7. Longitudinal studies of IPD in the United Kingdom have 
demonstrated serotype replacement following PCV13 intro-
duction [3]. Serotype replacement has also been demonstrated 
in colonization studies of children and their families: in 2015–
2016, 51.1% of children aged <5  years were colonized with 
nonvaccine-type pneumococci, compared with 1% who were 
colonized with PCV13 serotypes [4]. Parental colonization 
rates were low, with only 2.8% of parents testing positive in 
2015–2016.
Antimicrobial resistance rates among cases of pneumococcal 
colonization and disease vary markedly between different 
European countries [5, 6]. Resistance is relatively uncommon in 
the United Kingdom, with <10% of IPD isolates nonsusceptible 
to penicillin [5].
When comparing the serotypes found in IPD and those 
found in childhood colonization, there is some discordance. 
For example, serotype 8 has emerged as the commonest disease-
causing serotype [3], whereas no colonization with serotype 8 
was identified in the most recent childhood survey [4]. In ad-
dition, IPD studies have identified incomplete herd protection 
in adults against some PCV13 serotypes, particularly the highly 
virulent serotypes 3 and 19A, even though childhood coloni-
zation with these serotypes was exceedingly rare. This led the 
researchers to conclude that many disease-causing serotypes 
have high case-carrier ratios or perhaps only colonize for short 
durations [4]. It also suggests that serotype replacement in 
childhood colonization is an imperfect surrogate for replace-
ment in invasive disease.
Adults without regular contact with children may be 
less susceptible to the ecological effects of childhood PCV 
programs and thus could represent a reservoir of vaccine-type 
pneumococci [7]. However, studies of such populations are few, 
typified by low sampling yield and reliance on molecular detec-
tion methods, which limit their ability to identify serotypes and 
assess antimicrobial susceptibility [8].
Volunteers for the experimental human pneumococcal col-
onization (EHPC) research program in the Liverpool School 
of Tropical Medicine undergo screening for pneumococcal 
colonization prior to participation. In this article, we use these 
volunteers as a surrogate for the general healthy adult popu-
lation to report colonization rates, serotype distributions, and 
antimicrobial susceptibility profiles in healthy adults over the 
first 7 years of screening.
METHODS
The rationale, methods, and inclusion/exclusion criteria for 
EHPC studies have been previously reported [9]. In brief, the 
studies are open to healthy adults aged ≥18  years, excluding 
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those with important risk factors for pneumococcal disease, 
colonization, or transmission, including cigarette smoking, 
close contact with children aged <5 years, healthcare work or 
care-provider responsibilities, steroid therapy, and respiratory 
or immunosuppressive comorbidities. Recent antibiotic therapy 
(within 2 weeks) and prior pneumococcal vaccination are also 
exclusion criteria. The majority of study recruitment events are 
held in local universities.
All volunteers underwent nasal wash screening for 
community-acquired pneumococcal colonization at their first 
visit. We reviewed all screening nasal wash specimens obtained 
between October 2010 and March 2017. A  summary of the 
original studies is provided in the Supplementary Materials. 
All studies were approved by the local National Health Service 
Research Ethics Committee, and all participants provided 
written informed consent.
Nasal washes were performed as previously described [9]. In 
brief, 5 mL of 0.9% sodium chloride solution was introduced 
by a syringe into the nose, where it was held for a few seconds 
before being expelled into a sterile container. The participants 
were advised to occlude their pharynx (eg, by pressing their 
tongue against their hard palate) during the procedure, which 
was repeated twice in each nostril, resulting in the use of 20 mL 
of saline. Nasal wash samples were transported to the labora-
tory within 1 hour of collection, where they were plated on gen-
tamicin/blood agar and incubated overnight at 37°C with 5% 
CO2. Community-acquired pneumococcal colonization was 
defined as the identification of S. pneumoniae by using standard 
microbiological techniques, with serogroup identified by the 
latex agglutination test. Where required, the serotype was con-
firmed using the Senti-SP v1.6 molecular serotyping microarray 
(BUGS Bioscience) as previously described [10]. We tested all 
isolates for susceptibility to penicillin, clarithromycin, dox-
ycycline, levofloxacin, trimethoprim-sulfamethoxazole, and 
vancomycin, using disk diffusion and the Etest (bioMérieux, 
Basingstoke, United Kingdom), following the recommendations 
and clinical breakpoints of the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST, version 7.1 
[11]; Supplementary Materials). Zones of inhibition were meas-
ured by 2 independent reviewers, and all resistant isolates were 
tested a second time, for confirmation. We used meningitis 
breakpoints when interpreting penicillin minimum inhibitory 
concentrations.
For purposes of analysis, we assumed that maximal vac-
cine coverage of children aged <5 years with the primary series 
of PCV13 was achieved 5  years after its introduction [3]. We 
compared the proportion of individuals who were colonized, 
the proportion who were colonized with PCV13 serotypes, 
and the proportion of isolates displaying antibiotic-resistant 
phenotypes before and after 1 April 2015 (the early and late 
periods, respectively), by χ2 analysis or the Fisher exact test 
where appropriate, using SPSS version 24 (IBM, New York, NY).
RESULTS
A total of 795 healthy volunteers met the inclusion criteria and 
underwent nasal wash screening (Table 1). The median age 
was 21 years (interquartile range, 20–23 years), and 452 (57%) 
were female. Pneumococcal colonization was detected in 52 
participants (6.5%; 95% confidence interval [CI], 5.0%–8.5%).
We identified PCV13 serotypes in 17 of 52 (32.7%; Figure 1 
and Supplementary Table 3). Serotype 3 was the commonest 
isolate (10 of 52 isolates); the next most common vaccine 
types were 19A and 19F (3 isolates each). The most common 
nonvaccine types were 23B (5 isolates) and 8, 11A, 35F, and 
37 (4 isolates each). Colonization rates were not significantly 
different between the early and late periods (24 of 368 [6.5%] 
and 28 of 427 [6.6%], respectively; P = .98). Among colonized 
participants, 8 of 24 (33.3%) were carrying PCV13 serotypes 
before 1 April 2015, compared with 9 of 28 (32.1%) carrying 
PCV13 serotypes afterward (P = .93).
We identified resistance to at least 1 antibiotic in 8 of 52 
isolates (15.4%; 95% CI, 8.0%–27.5%; Supplementary Figure 1 
and Supplementary Table 4). The majority of resistant isolates 
(6 of 8) were nonvaccine types. The highest rate of resistance 
Table 1. Demographic Characteristics of Participants
 Non-colonized (n = 743) Colonized (n = 52) Total
Age, y, median (IQR) 21 (20–23) 21 (19–23) 21 (20–23)
Female sex, no. (%) 428 (57.6) 24 (46.2) 452 (56.9)
Year of screen, no. (% of annual total)    
 2010 8 (100) 0 8
 2011 65 (97) 2 (3) 67
 2012 129 (89.6) 15 (10.4) 144
 2013 31 (96.9) 1 (3.1) 32
 2014 66 (93) 5 (7) 71
 2015 154 (94.5) 9 (5.5) 163
 2016 178 (93.2) 13 (6.8) 191
 2017 112 (94.1) 7 (5.9) 119
Abbreviation: IQR, interquartile range.
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was against penicillin (5 of 8 isolates; all were susceptible to 
amoxicillin and ceftriaxone), followed by clarithromycin and 
doxycycline (4 of 8 each). We did not detect any levofloxacin 
or vancomycin resistance. We identified resistance to 3 anti-
biotic classes in 2 isolates and resistance to 2 classes in a fur-
ther 4 isolates. All resistant isolates were detected after 1 April 
2015 (8 of 28 [28.6%]), compared with 0 of 24 before this cutoff 
(P = .005).
DISCUSSION
We found a higher rate of colonization than has previously been 
reported in the general European adult population [1, 12]. This 
finding is notable given that the exclusion criteria for EHPC 
studies resulted in all participants lacking major risk factors for 
pneumococcal acquisition [9]. When our results are compared 
to those from a recent colonization study of United Kingdom 
children aged <5  years and their parents, we identified more 
frequent colonization and a greater range of serotypes than were 
found in the parents but less colonization and fewer serotypes 
than were found in the children [4].
Although our data collection spanned the first 7  years of 
PCV13 implementation, the relative distribution of serotypes 
did not change over this time. Our colonization patterns were 
dominated by nonvaccine types, reflecting current trends in 
IPD and colonization in the United Kingdom [3, 4]. Serotype 8 
is currently the commonest cause of IPD in the United Kingdom 
and was the joint third-most frequently detected serotype in our 
study, even though it was not detected in the most recent United 
Kingdom pediatric colonization survey [3, 4]. A cross-sectional 
study in 2010–2011 identified PCV13 serotypes (specifically 
3, 19F, and 19A) in 5 of 36 colonized United Kingdom adults 
[6]; we identified ongoing circulation of these same serotypes 
throughout the PCV13 era. This could explain why serotypes 
3 and 19A remain common in IPD even though they are rarely 
identified in pediatric colonization [3, 4]. This reservoir in 
young adults could have the potential to recolonize the pedi-
atric population after the United Kingdom reduces the child-
hood PCV13 schedule from 3 to 2 doses [13]. Conversely, the 
failure of the current pediatric vaccine schedule to generate 
herd protection against these serotypes could support a call for 
vaccination of at-risk adults, although the 23-valent pneumo-
coccal polysaccharide vaccine is already used for direct protec-
tion of this population in the United Kingdom.
While our study outperformed the pediatric colonization 
survey in detecting certain serotypes with invasive potential 
(eg, 3, 8, and 19A), the pediatric survey frequently identified 
carriage with invasive serotypes (eg, 15B/C and 10A) that were 
poorly represented in our cohort [4]. Therefore, it seems that 
colonization surveys should optimally include a wider range of 
subjects, rather than being restricted to households with chil-
dren. This would maximize their potential to quantify serotype 
replacement and complement IPD surveillance in guiding fu-
ture vaccine formulation recommendations.
Colonization studies have typically focused on children and 
their close contacts, to maximize the yield from screening. We 
are aware of one other study that deliberately recruited a con-
trol cohort of adults who lacked close contact with children 
[8]. The authors detected colonization in 10% of Dutch parents 
(29 of 298)  versus 2% of controls (5 of 323), using culture-
based methods. Molecular testing increased the yield to 7% in 
controls (21 of 323), similar to our findings, which were based 
on culture-based methods in United Kingdom adults.
Antimicrobial resistance in pneumococci is a growing global 
health concern [14]. We detected the emergence of antimicrobial 
resistance during the later period of this study, with no resistant 
isolates identified during the early period. However, a cross-sec-
tional study including data from United Kingdom primary care 
practices in 2010 identified cases of resistant pneumococcal 
colonization in adults, suggesting that the absence of resistance 
in the early years of our data collection may be due to either 
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Figure 1.  Serotype distribution among subjects colonized with vaccine serotypes (left) or nonvaccine serotypes (right) before (white bars) and after (gray bars) the 5-year 
anniversary of the introduction of the 13-valent pneumococcal vaccine (PCV13) in the United Kingdom.
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chance or specific local factors [1]. The resistance profiles of dif-
ferent pneumococcal serotypes in adult colonization have not 
been previously reported in the United Kingdom. Although 
our numbers are small, it is concerning that the majority of 
resistant isolates displayed resistance to >1 class of antibiotic. 
Clustering of resistance in nonvaccine types suggests that the 
childhood PCV13 program is unlikely to reduce this reservoir 
of antimicrobial resistance in the community.
The main constraint of the study is the limited demographic 
and medical history data available. However, the strict inclu-
sion criteria mandated by EHPC studies should have resulted 
in a homogeneous study population, defined by the absence of 
significant risk factors for pneumococcal colonization. Another 
limitation is that our sampling was performed in a single city. 
Culture-based colonization determination, allowing accurate 
serotyping and resistance measurement, is a strength of our 
study—molecular testing of oropharyngeal samples may have 
increased our yield but would not have allowed phenotypic 
confirmation of antimicrobial resistance [8]. Our use of nasal 
wash specimens, rather than nasal or nasopharyngeal swab 
specimens, may have contributed to the high pneumococcal 
yield obtained in this study [15]: a study using nasal swabs in 
>3000 United Kingdom adults only identified colonization in 
1.8% of participants [1].
In summary, we described pneumococcal colonization in 
a population of adults not normally targeted by colonization 
studies, including the persistence of some PCV13 serotypes, 
epidemiologically important nonvaccine types, and emerging 
antimicrobial resistance. Inclusion of a wider sample of adults 
in colonization studies would complement ongoing surveil-
lance of IPD isolates to inform national pneumococcal vacci-
nation policies.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors 
to benefit the reader, the posted materials are not copyedited 
and are the sole responsibility of the authors, so questions or 
comments should be addressed to the corresponding author.
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